Cargando…

Concurrent and predictive validity of the Alberta Infant Motor Scale and the Peabody Developmental Motor Scales-2 administered to infants born preterm in Norway

BACKGROUND: The correlation between the Alberta Infant Motor Scale (AIMS) and the Peabody Developmental Motor Scales-2 (PDMS-2) has not previously been assessed in Norwegian infants. Our purpose was to investigate the concurrent validity of the AIMS and the PDMS-2 in a group of high-risk infants, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ustad, Tordis, Brandal, Merethe, Campbell, Suzann K., Girolami, Gay L., Sinding-Larsen, Charlotte, Øberg, Gunn Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666346/
https://www.ncbi.nlm.nih.gov/pubmed/37993837
http://dx.doi.org/10.1186/s12887-023-04402-6
_version_ 1785148929192493056
author Ustad, Tordis
Brandal, Merethe
Campbell, Suzann K.
Girolami, Gay L.
Sinding-Larsen, Charlotte
Øberg, Gunn Kristin
author_facet Ustad, Tordis
Brandal, Merethe
Campbell, Suzann K.
Girolami, Gay L.
Sinding-Larsen, Charlotte
Øberg, Gunn Kristin
author_sort Ustad, Tordis
collection PubMed
description BACKGROUND: The correlation between the Alberta Infant Motor Scale (AIMS) and the Peabody Developmental Motor Scales-2 (PDMS-2) has not previously been assessed in Norwegian infants. Our purpose was to investigate the concurrent validity of the AIMS and the PDMS-2 in a group of high-risk infants, and to investigate the predictive validity of the two tests for atypical motor function at 24 months post term age (PTA). METHODS: This is a retrospective study of the AIMS and the PDMS-2 administered to infants born preterm with gestational age ≤ 32 weeks (n = 139) who had participated in a randomized controlled trial of early parent-administered physiotherapy. The infants’ motor development had been assessed using the AIMS and the PDMS-2 at 6- and 12-months. The primary outcome was PDMS-2 at 24-months PTA. To explore the correlation between the two tests we used Spearman’s rho. Bland Altman plots were used to detect if there were systematic differences between the measurements. Receiver-operating characteristics curves were used to calculate area under the curve as an estimate of diagnostic accuracy of the AIMS and the PDMS- with respect to motor outcome at 24 months. RESULTS: The correlation between the AIMS and the PDMS-2 (total motor and locomotion subscale), at 6 months, was r = 0.44 and r = 0.76, and at 12 months r = 0.56 and r = 0.80 respectively. The predictive validity for atypical motor function at 24 months, assessed using the area under the curve at 6- and at 12- months, was for the AIMS 0.87 and 0.86, respectively, and for the PDMS-2 locomotion subscale 0.82 and 0.76 respectively. CONCLUSION: The correlation between the AIMS and the PDMS-2 locomotion subscale, at 6- and 12- months PTA, was good to excellent in a group of infants born preterm in Norway. And the AIMS and the locomotion subscale of the PDMS-2 were equally good predictors for atypical motor outcomes at 24 months PTA. These findings indicate that the AIMS and the locomotion subscale of the PDM-2, could be used interchangeable when assessing motor development in infants at 6- or 12 months of age. TRIAL REGISTRATION: ClinicalTrials.gov NCT01089296. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-023-04402-6.
format Online
Article
Text
id pubmed-10666346
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106663462023-11-23 Concurrent and predictive validity of the Alberta Infant Motor Scale and the Peabody Developmental Motor Scales-2 administered to infants born preterm in Norway Ustad, Tordis Brandal, Merethe Campbell, Suzann K. Girolami, Gay L. Sinding-Larsen, Charlotte Øberg, Gunn Kristin BMC Pediatr Research BACKGROUND: The correlation between the Alberta Infant Motor Scale (AIMS) and the Peabody Developmental Motor Scales-2 (PDMS-2) has not previously been assessed in Norwegian infants. Our purpose was to investigate the concurrent validity of the AIMS and the PDMS-2 in a group of high-risk infants, and to investigate the predictive validity of the two tests for atypical motor function at 24 months post term age (PTA). METHODS: This is a retrospective study of the AIMS and the PDMS-2 administered to infants born preterm with gestational age ≤ 32 weeks (n = 139) who had participated in a randomized controlled trial of early parent-administered physiotherapy. The infants’ motor development had been assessed using the AIMS and the PDMS-2 at 6- and 12-months. The primary outcome was PDMS-2 at 24-months PTA. To explore the correlation between the two tests we used Spearman’s rho. Bland Altman plots were used to detect if there were systematic differences between the measurements. Receiver-operating characteristics curves were used to calculate area under the curve as an estimate of diagnostic accuracy of the AIMS and the PDMS- with respect to motor outcome at 24 months. RESULTS: The correlation between the AIMS and the PDMS-2 (total motor and locomotion subscale), at 6 months, was r = 0.44 and r = 0.76, and at 12 months r = 0.56 and r = 0.80 respectively. The predictive validity for atypical motor function at 24 months, assessed using the area under the curve at 6- and at 12- months, was for the AIMS 0.87 and 0.86, respectively, and for the PDMS-2 locomotion subscale 0.82 and 0.76 respectively. CONCLUSION: The correlation between the AIMS and the PDMS-2 locomotion subscale, at 6- and 12- months PTA, was good to excellent in a group of infants born preterm in Norway. And the AIMS and the locomotion subscale of the PDMS-2 were equally good predictors for atypical motor outcomes at 24 months PTA. These findings indicate that the AIMS and the locomotion subscale of the PDM-2, could be used interchangeable when assessing motor development in infants at 6- or 12 months of age. TRIAL REGISTRATION: ClinicalTrials.gov NCT01089296. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-023-04402-6. BioMed Central 2023-11-23 /pmc/articles/PMC10666346/ /pubmed/37993837 http://dx.doi.org/10.1186/s12887-023-04402-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ustad, Tordis
Brandal, Merethe
Campbell, Suzann K.
Girolami, Gay L.
Sinding-Larsen, Charlotte
Øberg, Gunn Kristin
Concurrent and predictive validity of the Alberta Infant Motor Scale and the Peabody Developmental Motor Scales-2 administered to infants born preterm in Norway
title Concurrent and predictive validity of the Alberta Infant Motor Scale and the Peabody Developmental Motor Scales-2 administered to infants born preterm in Norway
title_full Concurrent and predictive validity of the Alberta Infant Motor Scale and the Peabody Developmental Motor Scales-2 administered to infants born preterm in Norway
title_fullStr Concurrent and predictive validity of the Alberta Infant Motor Scale and the Peabody Developmental Motor Scales-2 administered to infants born preterm in Norway
title_full_unstemmed Concurrent and predictive validity of the Alberta Infant Motor Scale and the Peabody Developmental Motor Scales-2 administered to infants born preterm in Norway
title_short Concurrent and predictive validity of the Alberta Infant Motor Scale and the Peabody Developmental Motor Scales-2 administered to infants born preterm in Norway
title_sort concurrent and predictive validity of the alberta infant motor scale and the peabody developmental motor scales-2 administered to infants born preterm in norway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666346/
https://www.ncbi.nlm.nih.gov/pubmed/37993837
http://dx.doi.org/10.1186/s12887-023-04402-6
work_keys_str_mv AT ustadtordis concurrentandpredictivevalidityofthealbertainfantmotorscaleandthepeabodydevelopmentalmotorscales2administeredtoinfantsbornpreterminnorway
AT brandalmerethe concurrentandpredictivevalidityofthealbertainfantmotorscaleandthepeabodydevelopmentalmotorscales2administeredtoinfantsbornpreterminnorway
AT campbellsuzannk concurrentandpredictivevalidityofthealbertainfantmotorscaleandthepeabodydevelopmentalmotorscales2administeredtoinfantsbornpreterminnorway
AT girolamigayl concurrentandpredictivevalidityofthealbertainfantmotorscaleandthepeabodydevelopmentalmotorscales2administeredtoinfantsbornpreterminnorway
AT sindinglarsencharlotte concurrentandpredictivevalidityofthealbertainfantmotorscaleandthepeabodydevelopmentalmotorscales2administeredtoinfantsbornpreterminnorway
AT øberggunnkristin concurrentandpredictivevalidityofthealbertainfantmotorscaleandthepeabodydevelopmentalmotorscales2administeredtoinfantsbornpreterminnorway